Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Mar 26

PMID 35336021

Authors

Efthymios Neroutsos

Ricardo Nalda-Molina

Anna Paisiou

Kalliopi Zisaki

Evgenios Goussetis

Alexandros Spyridonidis

Vasiliki Kitra

Stelios Grafakos

Georgia Valsami

Aristides Dokoumetzidis

Affiliations

Soon will be listed here.

Abstract

We develop a population pharmacokinetic model to describe Busulfan pharmacokinetics in paediatric patients and investigate by simulations the impact of various sampling schedules on the calculation of AUC. Seventy-six children had 2 h infusions every 6 h. A two-compartment linear model was found to adequately describe the data. A lag-time was introduced to account for the delay of the administration of the drug through the infusion pump. The mean values of clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution were 10.7 L/h, 39.5 L, 4.68 L/h and 17.5 L, respectively, normalized for a Body Weight (BW) of 70 kg. BW was found to explain a portion of variability with an allometric relationship and fixed exponents of 0.75 on clearance parameters and 1 on volumes. Interindividual variability for clearance and volume of distribution was found to be 28% and 41%, respectively, and interoccasion variability for clearance was found to be 11%. Three sampling schedules were assessed by simulations for bias and imprecision to calculate AUC by a non-compartmental and a model-based method. The latter was found to be superior in all cases, while the non-compartmental was unbiased only in sampling up to 12 h corresponding to a once-daily dosing regimen.

Citing Articles

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective.

Briki M, Andre P, Thoma Y, Widmer N, Wagner A, Decosterd L Pharmaceutics. 2023; 15(4).

PMID: 37111768 PMC: 10147065. DOI: 10.3390/pharmaceutics15041283.

In Silico Pharmacology for Evidence-Based and Precision Medicine.

Spanakis M Pharmaceutics. 2023; 15(3).

PMID: 36986874 PMC: 10054111. DOI: 10.3390/pharmaceutics15031014.

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.

Dadkhah A, Wicha S, Kroger N, Muller A, Pfaffendorf C, Riedner M Pharmaceutics. 2022; 14(6).

PMID: 35745718 PMC: 9229330. DOI: 10.3390/pharmaceutics14061145.

References

Hassan M . The role of busulfan in bone marrow transplantation. Med Oncol. 1999; 16(3):166-76. DOI: 10.1007/BF02906128. View

Grochow L, Jones R, Brundrett R, Braine H, Chen T, Saral R . Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989; 25(1):55-61. DOI: 10.1007/BF00694339. View

Bartelink I, Bredius R, Belitser S, Suttorp M, Bierings M, Knibbe C . Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009; 15(2):231-41. DOI: 10.1016/j.bbmt.2008.11.022. View

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

Bartels K, Moss D, Peterfreund R . An analysis of drug delivery dynamics via a pediatric central venous infusion system: quantification of delays in achieving intended doses. Anesth Analg. 2009; 109(4):1156-61. DOI: 10.1213/ane.0b013e3181b220c9. View

Andersson B, Thall P, Madden T, Couriel D, Wang X, Tran H . Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85. DOI: 10.1053/bbmt.2002.v8.pm12374452. View

Lovich M, Kinnealley M, Sims N, Peterfreund R . The delivery of drugs to patients by continuous intravenous infusion: modeling predicts potential dose fluctuations depending on flow rates and infusion system dead volume. Anesth Analg. 2006; 102(4):1147-53. DOI: 10.1213/01.ane.0000198670.02481.6b. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Ansari M, Theoret Y, Rezgui M, Peters C, Mezziani S, Desjean C . Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit. 2013; 36(1):93-9. DOI: 10.1097/FTD.0b013e3182a04fc7. View

10.

Slattery J, Clift R, Buckner C, Radich J, Storer B, Bensinger W . Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89(8):3055-60. View

11.

Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D . Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2013; 383(9915):436-48. DOI: 10.1016/S0140-6736(13)62069-3. View

12.

Peterfreund R, Philip J . Critical parameters in drug delivery by intravenous infusion. Expert Opin Drug Deliv. 2013; 10(8):1095-108. DOI: 10.1517/17425247.2013.785519. View

13.

Ward J, Kletzel M, Duerst R, Fuleihan R, Chaudhury S, Schneiderman J . Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. Biol Blood Marrow Transplant. 2015; 21(9):1612-21. DOI: 10.1016/j.bbmt.2015.05.017. View

14.

Andersson B, Kashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P . Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002; 8(3):145-54. DOI: 10.1053/bbmt.2002.v8.pm11939604. View

15.

Neroutsos E, Athanasiadou I, Paisiou A, Zisaki K, Goussetis E, Archontaki H . Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time. J Pharm Pharmacol. 2021; 73(10):1340-1350. DOI: 10.1093/jpp/rgab087. View

16.

Lovich M, Doles J, Peterfreund R . The impact of carrier flow rate and infusion set dead-volume on the dynamics of intravenous drug delivery. Anesth Analg. 2005; 100(4):1048-1055. DOI: 10.1213/01.ANE.0000146942.51020.88. View

17.

Bartelink I, Lalmohamed A, van Reij E, Dvorak C, Savic R, Zwaveling J . Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016; 3(11):e526-e536. PMC: 5159247. DOI: 10.1016/S2352-3026(16)30114-4. View

18.

Tutschka P, SANTOS G . Bone marrow transplantation in the busulfan-treated rat. II. Effect of cyclophosphamide and antithymic serum on the presensitized state. Transplantation. 1975; 20(2):116-22. DOI: 10.1097/00007890-197508000-00004. View

19.

Ljungman P, Hassan M, Bekassy A, Ringden O, Oberg G . High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1998; 20(11):909-13. DOI: 10.1038/sj.bmt.1700994. View

20.

Russell J, Tran H, Quinlan D, Chaudhry A, Duggan P, Brown C . Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002; 8(9):468-76. DOI: 10.1053/bbmt.2002.v8.pm12374451. View